Recombinant Anti-MDH1 antibody [EPR13596(B)] (ab181091)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR13596(B)] to MDH1
- Suitable for: Flow Cyt (Intra), WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-MDH1 antibody [EPR13596(B)]
See all MDH1 primary antibodies -
Description
Rabbit monoclonal [EPR13596(B)] to MDH1 -
Host species
Rabbit -
Tested applications
Suitable for: Flow Cyt (Intra), WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human spleen, HepG2 and Jurkat lysates; Jurkat cells.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 59% PBS, 0.05% BSA -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR13596(B) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab181091 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt (Intra) |
1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
|
WB |
1/1000 - 1/2000. Detects a band of approximately 36 kDa (predicted molecular weight: 36 kDa).
|
Notes |
---|
Flow Cyt (Intra)
1/100. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
WB
1/1000 - 1/2000. Detects a band of approximately 36 kDa (predicted molecular weight: 36 kDa). |
Target
-
Sequence similarities
Belongs to the LDH/MDH superfamily. MDH type 2 family. -
Post-translational
modificationsISGylated. -
Cellular localization
Cytoplasm. - Information by UniProt
-
Database links
- Entrez Gene: 4190 Human
- Entrez Gene: 17449 Mouse
- Entrez Gene: 24551 Rat
- Omim: 154200 Human
- SwissProt: P40925 Human
- SwissProt: P14152 Mouse
- SwissProt: O88989 Rat
- Unigene: 526521 Human
see all -
Alternative names
- cytoplasmic antibody
- Cytosolic malate dehydrogenase antibody
- Diiodophenylpyruvate reductase antibody
see all
Images
-
Intracellular flow cytometric analysis of 2%paraformaldehyde-fixedJurkat cells labeling MDH1 with ab181091 at 1/100 dilution (red) compared to a Rabbit monoclonal IgG isotype control (green), followed by Goat anti rabbit IgG (FITC) secondary antibody at 1/150 dilution.
-
All lanes : Anti-MDH1 antibody [EPR13596(B)] (ab181091) at 1/2000 dilution
Lane 1 : Human spleen lysate
Lane 2 : HepG2 cell lysate
Lane 3 : HeLa cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 36 kDa
Observed band size: 36 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (2)
ab181091 has been referenced in 2 publications.
- Li H et al. CMap analysis identifies Atractyloside as a potential drug candidate for type 2 diabetes based on integration of metabolomics and transcriptomics. J Cell Mol Med 24:7417-7426 (2020). PubMed: 32469143
- Kitazawa S et al. Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. Oncotarget 8:28922-28938 (2017). WB . PubMed: 28423651